Indeed, TBX2 confers resistance to temozolomide in glioblastoma, cisplatin in breast cancer and melanoma and platinum‐based chemotherapeutics in ovarian serous carcinoma [10, 43]. Here, TBX2 is linked to breast carcinoma.